Share & Earn


9 Meters Scores Patent for Hyperphagia, Obesity-Fighting Drug

0 2 years ago

9 Meters Biopharma has received notice from the U.S. Patent and Trademark Office (USPTO) allowing its patent for therapeutic NM-136, which is intended for the treatment of hyperphagia (extreme hunger), obesity and for reducing fatty tissue buildup in body organs.

9 Meters acquired NM-136 in July 2021, announcing that the first planned indication for the drug was for Prader-Willi Syndrome (PWS). PWS affects approximately 350,000-400,000 individuals worldwide and is a genetic multisystem disorder that causes low muscle tone, cognitive deficits and a chronic feeling of hunger. It can lead to excessive eating and life-threatening obesity due to metabolisms that use fewer calories than normal. Some patients face life-threatening gastrointestinal complications from episodes of binge eating.

Targeting hyperphagia in those with PWS is important as it can lead to compounding conditions, and NM-136 promises to do just that. The drug is a long-acting, highly specific humanized anti-GIP monoclonal antibody that prevents the glucose-dependent insulinotropic polypeptide (GIP) from binding to its receptor. GIP is a hormone that is produced by the small intestine in response to eating food, with its main action encouraging the release of insulin in the bloodstream.

GIP is also known to increase the amount of fat in the body by increasing the formation of fat cells. GIP can become overexpressed and increase its concentration when people engage in overeating, making it a prime target for therapeutics hoping to combat the negative effects of excessive hunger. In preclinical models of obesity, preventing GIP binding has significantly decreased weight and abdominal fat by reducing nutrient absorption from the intestine as well as nutrient storage.


Leave a Comment

Your email address will not be published. Required fields are marked *